Our Platform
Technology Used
APT Oncology utilizes a clinically validated TCR discovery and characterization platform that has successfully generated neoantigen TCR-Ts used in human clinical trials. Our platform provides an integrated, non-viral workflow for seamless development from target identification to drug manufacturing.
A Clinically Validated Process
- Predict & Prioritize Targets – Identify and rank the most promising therapeutic targets.
- Generate Target Library for Screening – Develop peptide-HLA (pHLA) libraries for in-depth screening.
- Capture T Cells that Bind to Target Library – Isolate T cells with the desired specificity.
- Functional Verification of TCR Activity – Confirm the effectiveness of selected TCRs.
- Safety & Pharmacology Preclinical Testing – Evaluate potential off-target effects and safety.
- Generate Plasmid & Cell Product – Manufacture cell therapies with proven quality control methods.
With the formation of APT Oncology, Pathfinder and Amplify’s combined expertise is advancing personalized solutions for patients. By integrating these capabilities, APT Oncology will rapidly advance TCR-based therapies from discovery to clinical application.
Have additional questions?
We’re here to help. Let’s talk.